Furious about damage inflicted by its Monsanto takeover, 55.5% of Bayer shareholders slapped management with a no-confidence vote at Friday’s shareholder meeting. But the vote was merely symbolic, not legally binding—and some prominent investors want to keep it that way.
read moreThe 2019 PharmaTimes Sales Awards have been enhanced to deliver a clinical, innovative and rigorous judging process to help further develop healthcare sales professionals. More: Dr Jim Golby reveals what makes the PharmaTimes Sales Awards such a unique challenge Source:
read moreAs Regeneron’s Eylea continues its reign as one of the best-selling drugs in the world, the company’s executives have been on the receiving end of massive pay packages. For CEO Len Schleifer, 2018 was no different. More: With Eylea still
read moreBiogen has faced rebellious investors before. Ten years ago, it confronted a proxy fight with activist Carl Icahn that ended with two new directors on its board. So in a way, it’s no surprise the biotech is expanding its board
read moreThe approval is for adjunct use to insulin therapy to improve blood sugar control in adults. More: Zynquista approved in EU for certain patients with type I diabetes Source: News
read moreThe ELLIPSE trial is the first Phase III trial completed in over a decade in children and adolescents with type II diabetes. More: Novo Nordisk’s Victoza found to cut blood sugar in children Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals